June 15, 2022
Novartis creates Online Resource for Practitioners
June 6, 2022
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) Demonstrates Unprecedented Efficacy in Pediatric Patients with BRAF V600 Low-Grade Gliomas in Phase II/III Study
May 23, 2022
Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA Positive Metastatic Castration-Resistant Prostate Cancer
No current content.